Po. Livingston et al., Autoimmune and antitumor consequences of antibodies against antigens shared by normal and malignant tissues, J CLIN IMM, 20(2), 2000, pp. 85-93
There is now a considerable body of information documenting the autoimmune
consequences of antibodies induced by growing malignancies, or by passively
administered and actively induced antibodies, in cancer patients against:
antigens shared by normal and malignant tissues. This provides a rich sourc
e of information addressing the consequences of autoantibodies against a ra
nge of antigens. Antibodies against cell-surface or intracellular antigens
in the central nervous system (CNS) or on epithelial surfaces of normal tis
sues do not generally result in autoimmunity, but the same types and titers
of antibodies against cell surface antigens in the subepidermal skin, peri
pheral nerves, blood, or vascular sites such as the spleen and bone marrow
readily induce autoimmunity. The blood brain barrier of the CNS and apical
antigen expression and the basement membrane in epithelial tissues, may pro
tect these sites from antibody induced damage. Cancer cells, however, are p
rotected by neither unidirectional antigen expression nor basement membrane
s. Vaccine induced antibodies against a variety of cancer cell surface anti
gens have been associated with prevention of turner recurrence in preclinic
al models and in vaccinated cancer patients, in the absence of demonstrable
autoimmunity. This forms the basis for a series of ongoing Phase III trial
s with single or polyvalent antigen cancer vaccines designed for optimal an
tibody induction.